Blood test may predict who benefits from lung cancer combo therapy
NCT ID NCT07392073
First seen Feb 06, 2026 · Last updated Jun 13, 2026 · Updated 19 times
Summary
This study aims to see if changes in certain immune cells in the blood can predict how well advanced lung cancer patients respond to a combination of chemotherapy and immunotherapy. About 80 adults with stage IIIB or IV non-small cell lung cancer will give blood samples before and after their first two treatment cycles. The goal is to find a better way to identify who will benefit most from this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.